From Absorbable Sutures to "Collagen Stimulator" Injections and Everyday Skincare: Polylactic Acid's 90-Year Rise, Now Entering Contract Manufacturers as a New "Cosmetic Registration" Ingredient

In the past two years, "regeneration," "degradable," and "bio-based" have become high-frequency terms in the skincare world. One ingredient that cannot be avoided is polylactic acid (PLA). On one hand, it is the core material of medical aesthetics "collagen stimulator" injections; on the other, it is entering formulation lists as a cosmetic ingredient. This ingredient, which sounds technical but actually has nearly a century of application history, what kind of "identity transformation" has it undergone? What does it mean for those building skincare brands and looking for contract manufacturers? We sort out this line clearly based on public information.

I. Nearly a Century of a "Grain of Rice": How Polylactic Acid Came to Be

Polylactic Acid (PLA) is a polymer material made from biomass raw materials containing starch or sugar, such as corn, cassava, and sugarcane, through microbial fermentation to produce lactic acid and then polymerization. Its biggest feature is good biocompatibility, gradual degradation under specific conditions, with the final products being carbon dioxide and water.

According to the Chinese Academy of Sciences' China Science Daily and public industry information, this technical line has taken nearly a century:

• 1780: Swedish chemist Scheele first isolated lactic acid from sour milk;
• 1913: Scientists first synthesized low-molecular-weight polylactic acid by polycondensation;
• 1932: Carothers, a scientist at the American company DuPont, who later invented nylon, produced higher-molecular-weight polylactic acid using the lactide ring-opening polymerization method, laying the foundation for modern processes;
• Around 1962: American companies used polylactic acid to make surgical sutures absorbable by the human body, officially opening its medical door, and later used it for absorbable bone pins and bone plates;
• 2002: The American company NatureWorks achieved large-scale industrial production of polylactic acid, with its flagship plant having an annual capacity of 150,000 tons, taking this green polymer from medical use to broader fields such as packaging, fibers, and personal care.

In other words, polylactic acid is not a suddenly emerging "internet-famous ingredient," but a mature material whose safety in the human body has been repeatedly verified by decades of medical applications.

II. The "Collagen Stimulator" Era: PLLA Becomes a Class III Medical Device Star

What made polylactic acid famous in the medical aesthetics world is its left-handed configuration—poly-L-lactic acid (PLLA).

After injection into the deep skin, PLLA microspheres, as a degradable scaffold material, are slowly metabolized over a longer period and are clinically used to improve facial volume and texture. Precisely because it acts on the human body and is administered by injection, it is managed under the strictest device pathway in various countries:

• Internationally, PLLA fillers were first launched in the European Union in 1999 under the name New-Fill, later renamed Sculptra; approved by the U.S. FDA in 2004, initially for HIV-related facial lipoatrophy, and in 2009 expanded to aesthetic indications such as nasolabial folds in healthy people; according to Galderma official information, Sculptra was approved in China in 2024;
• In China, Changchun Sinobiom's Aivelan poly-L-lactic acid facial filler obtained the National Medical Products Administration Class III Medical Device Registration Certificate in April 2021, known as the first domestically compliant "collagen stimulator" injection, and was officially launched in August of the same year; Aimeike's "Rutian Tianshi" (L-lactic acid-ethylene glycol copolymer microsphere cross-linked sodium hyaluronate gel) was also approved in 2021.

It should be particularly noted that injecting PLLA is a medical procedure: historically, such products have had reports of adverse reactions such as nodules, closely related to reconstitution, injection depth, and technique, so they can only be used in compliant medical institutions by professionals using approved products. Unqualified "gray-market collagen stimulator" injections on the market are targets of long-term regulatory crackdowns.

III. The Key Leap: From "Material for Injection" to "Ingredient for Application"

A question many people care about is: since PLLA is so popular in medical aesthetics, can it be directly added to face creams, serums, and masks?

The key to the answer is distinguishing between two completely different identities: "injectable-grade medical device raw material" and "cosmetic-grade raw material."

1. Polylactic Acid (PLA, POLYLACTIC ACID): Has completed filing as a cosmetic ingredient (National Cosmetic Raw Material Filing No. 20220028). In cosmetic formulations, its legal purpose of use is film former, abrasive, emulsion stabilizer, emulsifier—in plain terms, it helps form a light film feel on the skin surface, provides a gentle physical skin-softening/exfoliating experience, and stabilizes emulsion systems. It is commonly found in serums, creams, masks, and gentle exfoliating products that replace traditional plastic microbeads.
2. Poly-L-Lactic Acid (PLLA): As a new cosmetic ingredient, it was filed by Guangdong Haoling (Zhongshan) Biotechnology Co., Ltd. in May 2026 (National Cosmetic Raw Material Filing No. 20260078). According to public company information, its cosmetic-grade PLLA microbeads, through particle size control and surface modification, can be used in cleansers, serums, creams, masks, etc., focusing on gentle exfoliation, improved skin feel, and film-forming moisturization.

There is a compliance red line that must be made clear: cosmetic-grade polylactic acid is "applied on the skin surface," and its mode of action is completely different from injectable-grade PLLA. No ordinary cosmetic may claim medical or injectable effects such as "stimulates collagen regeneration," "same as collagen stimulator injections," or "topical collagen stimulator." The new PLLA raw material is still in its safety monitoring period, and brands must strictly follow the filed purpose of use and safe dosage when using it. Holding this boundary is precisely the prerequisite for this ingredient to land healthily in the cosmetic registration track.

IV. Why Guangdong? The Greater Bay Area Cosmetics Industry Chain Has Caught This Wave of New Raw Materials

One detail worth noting: the company that obtained the PLLA new cosmetic ingredient filing is located in Zhongshan, Guangdong. This is no accident—Guangdong is the most concentrated region for the national cosmetics industry, and the Greater Bay Area industrial belt, with Guangzhou as the operations and R&D core and Foshan and Zhaoqing as production bases, happens to have the complete capability to undertake the landing of such new raw materials:

• Guangzhou: Dense with brand operations, formula R&D, packaging design, and marketing resources, convenient for concept planning and rapid sampling;
• Foshan: Mature cosmetics manufacturing foundation, suitable for large-scale OEM production of multiple dosage forms such as serums, creams, and masks;
• Zhaoqing: Modern production bases newly built in recent years, with advantages in clean workshops, automated production lines, and capacity flexibility, suitable for major clients and full-package customization.

For brands wanting to enter the polylactic acid concept, this division of labor—"R&D in Guangzhou, manufacturing in Foshan and Zhaoqing"—means that from a serum or a mask to a professional-line set, everything can be completed within the province through OEM processing and labeling or ODM custom R&D.

V. Brand Landing Suggestions: How to Use Polylactic Acid Raw Materials Safely

Based on raw material characteristics and regulatory requirements, here are several practical suggestions for brands planning new launches:

1. Choose the right efficacy entry point: Focus on film formation, moisturizing, soft skin feel, gentle exfoliation, and degradable/eco-friendly concepts, rather than copying medical aesthetics "collagen boosting" rhetoric;
2. Choose the right dosage form: Gentle exfoliating cleansers, wash-off masks, serums, creams, and tone-up creams are relatively easy directions to land; formulations must solve the suspension stability and particle size compatibility of polylactic acid microspheres;
3. Choose compliant factories: Prioritize Guangzhou/Foshan/Zhaoqing factories that hold cosmetics production licenses, have complete quality systems (such as ISO22716, GMPC), can provide raw material traceability and test reports, and can assist with ordinary cosmetics filing;
4. For new products, first do "supports customization": For products containing new raw materials in the monitoring period, it is recommended to confirm the formula and filing path one-on-one with the factory, proceed in a "new product recommendation · supports customization" manner, and after the client brand finalizes, complete the filing in the name of the commissioning party, which is more prudent;
5. Keep claims within boundaries: Do not touch expressions such as "injection," "injectable," "medical," or "collagen regeneration," and do not use clinical data from medical devices to endorse cosmetics.

From a suture that can be absorbed by the human body, to a "collagen stimulator" injection injected into the skin, to a skincare product that can be applied daily, polylactic acid has taken nearly a century to complete this "crossover." Its popularity shows that truly vital skincare ingredients rely on solid materials science and clear compliance boundaries. For Guangdong's cosmetics contract manufacturing industry, whether it can make such new raw materials standardized and stable is the key to turning a hot topic into long-term business.

The material history section of this article is synthesized from the Chinese Academy of Sciences' China Science Daily, NatureWorks official information, and public industry literature; medical aesthetics product information comes from FDA public documents, National Medical Products Administration public information, and official information from Galderma and Aivelan; cosmetic raw material filing information comes from public data from the National Medical Products Administration's cosmetic raw material filing. This article is for industry science popularization only and does not constitute medical advice. The use of the raw materials mentioned is subject to regulatory filing information. This article is industry news and does not recommend or sell any injectable medical devices; cosmetic efficacy claims are subject to regulatory filing/registration information.

Frequently Asked Questions (FAQ)

Q1: What is the difference between polylactic acid and poly-L-lactic acid (PLLA)?
PLLA is the left-handed configuration of polylactic acid. Injectable-grade PLLA is used in Class III medical devices (collagen stimulator injections), while cosmetics use polylactic acid that has completed cosmetic raw material filing or PLLA new raw materials within the monitoring period. The regulatory category and method of use are completely different.

Q2: Are skincare products containing polylactic acid safe?
Polylactic acid has good biocompatibility and is degradable. As a cosmetic raw material, it must be used within the filed purpose of use and safe dosage; sensitive skin is advised to do a local patch test first, and specifics are subject to product labels.

Q3: Does applying a polylactic acid serum equal getting a collagen stimulator injection?
No, and it cannot be promoted that way. Topical cosmetics act on the skin surface, while injectable-grade PLLA is a medical device that enters the deep skin. The two cannot replace each other.

Q4: Where in Guangdong can polylactic acid skincare products be contract manufactured?
The industrial chain in Guangzhou, Foshan, and Zhaoqing is complete. You can find OEM/ODM factories with cosmetics production licenses, able to assist with filing and with traceable raw materials, and sample first before mass production.

Q5: What should be noted for filing when using the new raw material PLLA to make products?
The new PLLA raw material is still in its safety monitoring period. Formulas must be designed strictly according to the filed use and safe dosage, and finished product filing must be completed in the name of the commissioning brand. It is recommended to confirm with the factory's compliance personnel throughout the process.